Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: New drugs, old side effects

Cutaneous and Ocular Toxicology

Volumn 33, Issue 1, 2014, Pages 1-6

  Patrizi, Annalisa ^a   Venturi, Michela ^a   Dika, Emi ^a   Maibach, Howard ^b   Tacchetti, Paola ^c   Brandi, Giovanni ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adverse drug reactions; Molecular cancer treatment; Skin

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; SKIN; THALIDOMIDE;

EID: 84894378234     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2013.787086     Document Type: Article

References (41)

1. Garcia-Navarro X, Puig L, Fernández-Figueras MT, et al. Bortezomib-associated cutaneous vasculitis. Br J Dermatol 2007;157:799-801.
2. Mariz JM, Esteves GV. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr Opin Oncol 2012; 24:S3-S11.
3. CTCAE-4.03-2010-06-14.xls s.d. Available from: http://evs.nci. nih.gov/ftp1/CTCAE/About.html [last accessed 23 Apr 2013].
4. Van de Donk NW, Görgün G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253-268.
5. Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403-1409.
6. Bonny M, Buyse V, Brochez L. Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clin Belg 2011;66:97-103.
7. Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009;3:294-299.
8. Sviggum HP, Davis MDP, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006;142: 1298-1302.
9. Min C-K, Lee S, Kim Y-J, et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006;76:265-268.
10. Van Regenmortel N, Van de Voorde K, De Raeve H, et al. Bortezomib-induced Sweet's syndrome. Haematologica 2005;90: ECR43.
11. Sanchez-Politta S, Favet L, Kerl K, et al. Bortezomib-induced skin eruption. Dermatology (Basel) 2008;216:156-158.
12. Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J. Am Acad Dermatol 2006;55:897-900.
13. Ozkurt ZN, Sucak GT, Aki SZ, et al. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma. Cutan Ocul Toxicol 2009;28:141-143.
14. Gerecitano J, Goy A, Wright J, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006;134:391-398.
15. Agterof MJ, Biesma DH. Images in clinical medicine. Bortezomib-induced skin lesions. N Engl J Med 2005;352:2534.
16. Pour L, Hajek R, Zdenek A, et al. Skin lesions induced by bortezomib. Haematologica 2005;90:ECR44.
17. Tanguy-Schmidt A, Avenel-Audran M, Croué A, et al. Bortezomib-induced acute neutrophilic dermatosis. Ann Dermatol Venereol 2009;136:443-446.
18. Thomas M, Cavelier Balloy B, et al. Bortezomib-induced neutrophilic dermatosis with CD30\+ lymphocytic infiltration. Ann Dermatol Venereol 2009;136:438-442.
19. Thuillier D, Lenglet A, Chaby G, et al. Bortezomib-induced eruption: sweet syndrome? Two case reports. Ann Dermatol Venereol 2009;136:427-430.
20. Knoops L, Jacquemain A, Tennstedt D, et al. Bortezomib-induced Sweet syndrome. Br J Haematol 2005;131:142.
21. Varettoni M, Vassallo C, Borroni G, et al. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol 2007;86:301-302.
22. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003;48:548-552.
23. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib- thalidomidedexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9-19.
24. Kuohung V, Goldberg LJ, Demierre M-F. Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction. J Am Acad Dermatol 2011;65:654-656.
25. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
26. Berg SL, Cairo MS, Russell H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 2011;29:316-323.
27. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053.
28. Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006;107:2609-2616.
29. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465.
30. Castelli R, Cannavò A, Conforti F, et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol 2012;34: 740-753.
31. Siniscalchi A, Tendas A, Morino L, et al. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Support Care Cancer 2012;20: 1585-1587.
32. Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Lenalidomide (revlimid), bortezomib (velcade) and dexamethasone (rvd) for heavily-pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 2013;54:555-560.
33. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749-760.
34. Castaneda CP, Brandenburg NA, Bwire R, et al. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol 2009;27:156-157.
35. Wäsch R, Jakob T, Technau K, et al. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol 2012;91:287-289.
36. Grape J, Frosch P. Papular drug eruption along the lines of Blaschko caused by lenalidomide. Hautarzt 2011;62:618-620.
37. Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology (Basel) 2010;220:49-50.
38. Tageja N, Giorgadze T, Zonder J. Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J 2011;41:286-288.
39. Hoverson AR, Davis MDP, Weenig RH, Wolanskyj AP. Neutrophilic dermatosis (Sweet syndrome) of the hands associated with lenalidomide. Arch Dermatol 2006;142:1070-1071.
40. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-2767.
41. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-5125.